Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical utility gene card for: Abetalipoproteinaemia

1. DISEASE CHARACTERISTICS

1.1 Name of the disease (synonyms)

Abetalipoproteinaemia (Bassen–Kornzweig syndrome).

1.2 OMIM# of the disease

200100.

1.3 Name of the analysed genes or DNA/chromosome segments

MTTP.

1.4 OMIM# of the gene(s)

157147.

1.5 Mutational spectrum

Over 30 mutations in MTTP have been described, mostly small point mutations (missense, nonsense and splicing) located throughout the gene's 18 exons.1, 2, 3, 4, 5, 6 The majority of mutations are ‘private’ to specific families or ethnic communities.

1.6 Analytical methods

DNA sequencing of genomic-exonic DNA with at least 20 bp of flanking intronic sequence. In patients where autosomal co-dominant inheritance can not be excluded or MTTP mutation(s) not identified, the APOB gene should be screened; homozygous familial hypobetalipoproteinaemia can give a similar biochemical and clinical phenotype to abetalipoproteinaemia.

1.7 Analytical validation

Where a mutation is identified using bi-directional DNA sequencing, the test is repeated from a fresh dilution of DNA for confirmation. When heterozygosity for two mutations is found, testing of the patient's parents is recommended, to confirm that the two mutations are present in trans (that is, on opposite chromosomes).

1.8 Estimated frequency of the disease (incidence at birth (‘birth prevalence’) or population prevalence)

Estimated at <1 in 1 000 000.1

1.9 If applicable, prevalence in the ethnic group of investigated person

Not applicable.

1.10 Diagnostic setting

Comment: Use of genetic testing is essentially limited for confirmatory diagnosis in a subject suspected to be affected, rather than other applications such as predictive testing or pre-natal diagnosis.

2. TEST CHARACTERISTICS

2.1 Analytical sensitivity (proportion of positive tests if the genotype is present)

Approximately 100%.

2.2 Analytical specificity (proportion of negative tests if the genotype is not present)

Approximately 100%.

2.3 Clinical sensitivity (proportion of positive tests if the disease is present)

The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.

Abetalipoproteinaemia is clinically characterised by the absence of apolipoprotein (apo) B-containing lipoproteins together with systemic clinical manifestations. All reported patients have fat malabsorption, acanthocytosis, marked hypocholesterolaemia and deficiency of plasma apoB and its associated lipoproteins, such as chylomicrons, very low-density lipoprotein and low-density lipoprotein (LDL).1 Most cases are complicated by retinitis pigmentosa, spinocerebellar ataxia and myopathy. Should this constellation of findings be present, there are two possibilities, namely, abetalipoproteinaemia or homozygous familial hypobetalipoproteinaemia caused by mutations in APOB. Family screening is useful in differentiating between these conditions, as obligate heterozygote parents of homozygous familial hypobetalipoproteinamia patients have one-quarter to one-third the absolute plasma concentration of LDL cholesterol and apoB, whereas obligate heterozygote parents of abetalipoproteinaemia patients have normal plasma lipid profiles.

2.4 Clinical specificity (proportion of negative tests if the disease is not present)

The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.

Approximately 100%.

2.5 Positive clinical predictive value (life-time risk of developing the disease if the test is positive)

100%.

2.6 Negative clinical predictive value (probability of not developing the disease if the test is negative)

Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.

Index case in that family had been tested:

100%.

Index case in that family had not been tested:

Should the constellation of clinical findings be present in an index case, it is possible that they might have homozygous familial hypobetalipoproteinaemia, rather than abetalipoproteinaemia. Homozygous familial hypobetalipoproteinaemia patients receive similar treatment advice as abetalipoproteinaemia patients. Also, there are even rarer conditions called homozygous proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency and familial combined hypolipidemia (due to homozygous mutations in angiopoietin-like protein 3, ANGPTL3) that present with extremely low (but not absent) levels of apoB-containing lipoproteins, but no systemic manifestations. To date, there are only a handful of families in the world reported with these latter two genetic conditions.

3. CLINICAL UTILITY

3.1 (Differential) diagnosis: The tested person is clinically affected

(To be answered if in 1.10 ‘A’ was marked)

3.1.1 Can a diagnosis be made other than through a genetic test?

3.1.2 Describe the burden of alternative diagnostic methods to the patient

Abetalipoproteinemia is characterised by the absence of plasma apoB-containing lipoproteins with marked hypocholesterolaemia, absence of LDL cholesterol and apoB and low triglyceride concentrations.1, 4, 5 In addition, increased serum transaminases due to hepatic steatosis, acanthocytosis and fat-soluble vitamin deficiency are found. Typically, abetalipoproteinaemia cannot be distinguished from homozygous familial hypobetalipoproteinaemia clinically.

3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?

Not applicable.

3.1.4 Will disease management be influenced by the result of a genetic test?

3.2 Predictive setting: The tested person is clinically unaffected but carries an increased risk based on family history

(To be answered if in 1.10 ‘B’ was marked)

3.2.1 Will the result of a genetic test influence lifestyle and prevention?

If the test result is positive (please describe).

If the test result is negative (please describe).

3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?

Not applicable.

3.3 Genetic risk assessment in family members of a diseased person

(To be answered if in 1.10 ‘C’ was marked)

3.3.1 Does the result of a genetic test resolve the genetic situation in that family?

Not applicable.

3.3.2 Can a genetic test in the index patient save genetic or other tests in family members?

Not applicable.

3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member?

Not applicable.

3.4 Prenatal diagnosis

(To be answered if in 1.10 ‘D’ was marked)

3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis?

4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING

Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe).

References

  1. 1

    Kane JP, Havel RJ : Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS et al (eds): The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001, 8th edn pp 2717–2752.

    Google Scholar 

  2. 2

    Shoulders CC, Brett DJ, Bayliss JD et al: Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum Mol Genet 1993; 2: 2109–2116.

    CAS  Article  Google Scholar 

  3. 3

    Sharp D, Blinderman L, Combs KA et al: Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993; 365: 65–69.

    CAS  Article  Google Scholar 

  4. 4

    Hooper AJ, van Bockxmeer FM, Burnett JR : Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci 2005; 42: 515–545.

    CAS  Article  Google Scholar 

  5. 5

    Zamel R, Khan R, Pollex RL, Hegele RA : Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis 2008; 3: 19.

    Article  Google Scholar 

  6. 6

    Narcisi TM, Shoulders CC, Chester SA et al: Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia. Am J Hum Genet 1995; 57: 1298–1310.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7

    Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR : The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Ann Rev Nutr 2000; 20: 663–697.

    CAS  Article  Google Scholar 

  8. 8

    Muller DP, Lloyd JK : Effect of large oral doses of vitamin E on the neurological sequelae of patients with abetalipoproteinemia. Ann NY Acad Sci 1982; 393: 133–144.

    CAS  Article  Google Scholar 

  9. 9

    Chowers I, Banin E, Merin S et al: Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients. Eye 2001; 15: 525–530.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported by EuroGentest2 (Unit 2: ‘Genetic testing as part of health care’), a Coordination Action under FP7 (Grant Agreement Number 261469) and the European Society of Human Genetics. RAH is supported by the Jacob J Wolfe Distinguished Medical Research Chair at the University of Western Ontario, the Edith Schulich Vinet Canada Research Chair in Human Genetics (Tier I), the Martha G Blackburn Chair in Cardiovascular Research, and operating grants from the CIHR (MOP-13430, MOP-79523, CTP-79853), the Heart and Stroke Foundation of Ontario (NA-6059, T-6018, PRG-4854), the Pfizer Jean Davignon Distinguished Cardiovascular and Metabolic Research Award, and Genome Canada through the Ontario Genomics Institute.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Robert A Hegele.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Burnett, J., Bell, D., Hooper, A. et al. Clinical utility gene card for: Abetalipoproteinaemia. Eur J Hum Genet 20, 1–3 (2012). https://doi.org/10.1038/ejhg.2012.30

Download citation

Search

Quick links